1-3 of 3
imp dehydrogenase
Close
Sort by
Journal Articles

Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Michael R. Kurman, MD, Courtney D. DiNardo, MD MSc, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Kiran Naqvi, MD MPH, Farhad Ravandi, MD, Elias J. Jabbour, MD, Ricardo Delumpa, BSN, Timothy Madden, PhD, Gary Maier, PhD, Hiroyuki Iwamura, PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1438.
https://doi.org/10.1182/blood-2018-99-116613
Published: 2018
Journal Articles

An Impdh Inhibitor, FF-10501 Possesses Activating Effects on Myeloid Differentiation As Well As Anti-Proliferation

Michiko Ichii, MD PhD, Motohiko Murase, MSc, Kensuke Komatsu, PhD, Motoki Saito, PhD, Jun Toda, MD, Kenji Oritani, MD PhD, Hiroyuki Iwamura, PhD, Yuzuru Kanakura, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3679.
https://doi.org/10.1182/blood.V126.23.3679.3679
Published: 2015
Journal Articles

Ribavirin-Induced Intracellular GTP Depletion Upregulates Factor VII Expression

Atsuo Suzuki, Yuhri Miyawaki, Eriko Okuyama, Moe Murata, Ando Yumi, Io Kato, Yuki Takagi, Akira Takagi, PhD, Takashi Murate, MD, PhD, Hidehiko Saito, MD, PhD, Tetsuhito Kojima, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1113.
https://doi.org/10.1182/blood.V120.21.1113.1113
Published: 2012